eNews
Home page > Comments


Comments

Analysis: Alimta patent seen as Lilly's "wild card"

04.01.2013. | NEW YORK (Reuters) - Eli Lilly & Co may have a $15 billion wild card up its sleeve as it waits for desperately needed new drugs to bear fruit....


Оставите Ваш коментр
*Име:

Е-пошта:


*Ваш коментар:
:) :D ;) B-) :P :-o :( x-(

*Сигурносни број: